EW Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.…
Industry Peers
Medical DevicesKey Statistics
About Edwards Lifesciences (NYSE: EW)
›
Edwards Lifesciences (NYSE: EW) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 16,000 employees.
The shares were at 101.85 USD on 20 November 2026, up 20.2% over 52 weeks. Its 52-week range is 74.66 USD to 108.00 USD: the price is 5.7% below the high and 36.4% above the low.
At a market capitalisation of 58.56B USD, it trades at 59.2 times trailing earnings and 30.1 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 24.9, a premium of 138% for EW.
Edwards Lifesciences reports return on equity of 10.4%, an operating margin of 28.8% and revenue up 10.5% year over year.
It holds more cash than debt, a net cash position of 3.94B USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 27 analysts cover the stock, with an average rating of Buy; their mean price target of 113.83 USD is 11.8% above the current price. The next earnings report is expected on 9 February 2027.